Stammdaten
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Unternehmen & Branche
| Name | XBiotech Inc. |
|---|---|
| Ticker | XBIT |
| CIK | 0001626878 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 78,4 Mio. USD |
| Beta | 0,83 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -45,540,000 | -1.49 | 150,082,000 | 140,350,000 | |
| 2025-09-30 | 10-Q | -6,008,000 | 172,424,000 | 167,080,000 | ||
| 2025-06-30 | 10-Q | -1,756,000 | 178,682,000 | 173,064,000 | ||
| 2025-03-31 | 10-Q | -10,884,000 | 181,864,000 | 174,713,000 | ||
| 2024-12-31 | 10-K | -38,531,000 | -1.26 | 199,093,000 | 182,268,000 | |
| 2024-09-30 | 10-Q | -5,015,000 | 209,851,000 | 192,115,000 | ||
| 2024-06-30 | 10-Q | -13,006,000 | 215,555,000 | 196,701,000 | ||
| 2024-03-31 | 10-Q | -10,002,000 | 227,858,000 | 209,280,000 | ||
| 2023-12-31 | 10-K | -4,635,000 | -0.81 | 226,615,000 | 218,846,000 | |
| 2023-09-30 | 10-K | -7,364,000 | ||||
| 2023-09-30 | 10-Q | -7,364,000 | 229,599,000 | 222,659,000 | ||
| 2023-06-30 | 10-K | -8,742,000 | ||||
| 2023-06-30 | 10-Q | -8,742,000 | 235,136,000 | 229,063,000 | ||
| 2023-03-31 | 10-Q | -3,816,000 | 242,121,000 | 236,905,000 | ||
| 2023-03-31 | 10-K | -3,816,000 | ||||
| 2022-12-31 | 10-K | -3,203,000 | -1.08 | 246,103,000 | 240,402,000 | |
| 2022-12-31 | 10-Q | -5,395,000 | 246,103,000 | 240,402,000 | ||
| 2022-09-30 | 10-K | -12,658,000 | ||||
| 2022-09-30 | 10-Q | -12,658,000 | 250,834,000 | 244,809,000 | ||
| 2022-06-30 | 10-Q | -11,644,000 | 266,462,000 | 255,795,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.